Humanigen is a clinical stage biopharmaceutical company, developing its portfolio of Humaneered® anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Co. is developing its primary product candidate, lenzilumab, for potential commercial use in several indications: as a therapeutic for patients newly hospitalized with COVID-19; as a prophylactic companion for certain chimeric antigen receptor therapy programs; for the prevention and/or treatment of acute graft versus host disease associated with bone marrow transfers; and as a therapeutic for chronic myelomonocytic leukemia. Co.'s other two product candidates, ifabotuzumab and HGEN005, are Humaneered monoclonal antibodies. The HGEN stock yearly return is shown above.
The yearly return on the HGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|